Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up

References

• Lamm D, Herr H, Jakse G, Kuroda M, Mostofi F, Okajima E, Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998;4:130–8.
   PubMedGoogle Scholar
• van der Meijden A, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48:363–71.
   PubMed Web of Science ®Google Scholar
• Wolf H, Højgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet 1983;ii:134–6.
   Google Scholar
• Wolf H, Melsen F, Pedersen S, Nielsen K. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994;157:147–51.
   PubMedGoogle Scholar
• Lamm D. Carcinoma in situ. Urol Clin North Am 1992;19:499–508.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011:59:997–1008.
   Google Scholar
• Böhle A, Bock P. Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682–6.
   PubMed Web of Science ®Google Scholar
• Sylvester R, van der Meijden A, Lamm D. Intravesical bacillus Calmette–Guérin reduces the risk of progression in patients with superficial bladder cancer; a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–70.
   PubMed Web of Science ®Google Scholar
• Gontero P, Böhle A, Malmström P-U, O'Donnell M, Oderda M, Sylvester R, The role of bacillus Calmette–Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010;57:410–29.
   PubMed Web of Science ®Google Scholar
• Malmström P-U, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E, An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56.
   PubMed Web of Science ®Google Scholar
• Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O, Alternating mitomycin C and bacillus Calmette–Guérin instillation therapy for carcinoma in situ of the bladder. J Urol 1995;154:2050–3.
   PubMed Web of Science ®Google Scholar
• Eksborg S, Nilsson S, Edsmyr F. Intravesical instillation of adriamycin. A model for standardization of the chemotherapy. Eur Urol 1980;6:218–20.
   PubMed Web of Science ®Google Scholar
• Jauhiainen K, Kangas L, Nieminen A, Käpylä H, Alfthan O. Optimizing mitomycin C activity during intravesical instillation. Urol Res 1983;11:59–62.
   PubMedGoogle Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistic arising in its consideration. Cancer Chemother Rep 1966;50:163–70.
   PubMedGoogle Scholar
• Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–54.
   Web of Science ®Google Scholar
• Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Sylvester R, van der Meijden A, Witjes A, Kurth K. Bacillus Calmette–Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–92.
   PubMed Web of Science ®Google Scholar
• Zlotta A, van Vooren J, Huygen K, Drowart A, Decock M, Pirson M, What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37:470–7.
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Rintala E, Pere A-K, Kallio J, Puolakka V-M, Liukkonen T, Weekly mitomycin C followed by monthly bacillus Calmette–Guérin or alternating monthly interferon-α2B and bacillus Calmette–Guérin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 2000;164:47–52.
   PubMed Web of Science ®Google Scholar
• Järvinen R, Kaasinen E, Sankila A, Rintala E; FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette–Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without CIS: a subgroup analysis of the prospective, randomized FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260–5.
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Wijkström H, Malmström P-U, Hellsten S, Duchek M, Mestad O, Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003;43:637–45.
   PubMed Web of Science ®Google Scholar
• de Reijke T, Kurth K, Sylvester R, Hall R, Brausi M, van de Beek K, Bacillus Calmette–Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer – Genitourinary-group phase III trial. J Urol 2005;173:405–9.
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A, Höltl W, Carpentier P, Spaander J, Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861. Eur Urol 2001;40:144–50.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro J, Martinez-Pineiro L, Solsona E, Rodriguez R, Gomez J, Martin M, Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242–7.
   PubMed Web of Science ®Google Scholar
• Kakiashvili D, van Rhijn B, Trottier G, Jewett Fleshner N, Finelli A, Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette–Guérin treatment. BJU Int 2010;107:540–4.
   PubMedGoogle Scholar
• Andius P, Damm O, Holmäng S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette–Guérin. Scand J Urol Nephrol 2004;38:285–90.
   PubMed Web of Science ®Google Scholar
• Zieger K, Jensen K. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette–Guérin immunotherapy on the outcome. Scand J Urol Nephrol 2011;45:411–18.
   PubMed Web of Science ®Google Scholar
• Cookson M, Herr H, Zhang ZF, Soloway M, Sogani P, Fair W. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62–7.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi MK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435–48.
   PubMed Web of Science ®Google Scholar